Amplification of chromosome 11q13 associated with primary resistance to PD-1 blockade in unresectable hepatocellular carcinoma
| Title | Amplification of chromosome 11q13 associated with primary resistance to PD-1 blockade in unresectable hepatocellular carcinoma |
|---|---|
| Description | A total of 62 HCC patients who underwent next-generation sequencing were retrospectively included in our department for this study. PD-1 inhibitors intervention (PD-1Ab) group and nonPD-1Ab group included 20 and 13 patients, respectively. Chromosome 11q13 amplification (Amp11q13) was the most common copy number variation in our cohort. Fifteen patients harbored Amp11q13 in our dataset. Des-y-carboxy- prothrombin (DCP), albumin (ALB), tumor number and portal vein tumor thrombus (PVTT) were different between the Amp11q13 group and the nonAmp11q13 group. In the PD-1Ab group, the proportion of primary resistance in patients with Amp11q13 was significantly higher than that in patients with nonAmp11q13. In the PD-1Ab group, the median progression-free survival (PFS) was 1.5 months in Amp11q13 patients vs 16.2 months in non-Amp11q13 patients. HCC patients with Amp11q13 are less likely to benefit from PD-1 blockade therapies. These findings may help guide the use of immunotherapy for HCC in routine clinical practice. |
| Organism | Homo sapiens |
| Data Type | Clinical Research data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA013528 |
| Release Date | 2022-11-29 |
| Submitter | Dongyu Liu (dongyu.liu@3dmedcare.com) |
| Organization | 3D Medicines Inc. |
| Submission Date | 2022-11-28 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX002465-01 | mutation.zip | 1 | Clinical Research data | 367.0 KB | zip | 0 | Controlled |